Antimicrobial peptides stage a comeback von Fox, Jeffrey L

Volltext

Master Protocol for squamous cell lung cancer readies for launch von Fox, Jeffrey L

Volltext

350 million in new funding for brain research von Fox, Jeffrey L

Volltext

Obama catapults patient-empowered Precision Medicine von Fox, Jeffrey L

Volltext

Agricultural probiotics enter spotlight von Fox, Jeffrey L

Volltext

Fraunhofer to mine Sanofi microbial collection von Fox, Jeffrey L

Volltext

Anthrax drug first antibacterial mAb to win approval von Fox, Jeffrey L

Volltext

Second MRSA antibiotic reaches the market von Fox, Jeffrey L

Volltext

Technology comes to typing von Fox, Jeffrey L

Volltext

Mars collaborates to sequence Africa's neglected food crops von Fox, Jeffrey L

Volltext

First vanguard anti-MRSA agent approved von Fox, Jeffrey L

Volltext

Indiana jumps the biosimilars gun von Fox, Jeffrey L

Volltext

FDA launches two research centers with academia von Fox, Jeffrey L

Volltext

NIH 'hubs' aid translation von Fox, Jeffrey L

Volltext

Rare-disease drugs boosted by new Prescription Drug User Fee Act von Fox, Jeffrey L

Volltext

Debate over details of US biosimilar pathway continues to rage von Fox, Jeffrey L

Volltext

Fecal transplants to follow FDA rules von Fox, Jeffrey L

Volltext

Volunteer GM wheat, mischief or carelessness? von Fox, Jeffrey L

Volltext

FDA moves on breakthrough therapies von Fox, Jeffrey L

Volltext

The business of developing antibacterials von Fox, Jeffrey L

Volltext